SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

USFDA concludes inspection at Alembic Pharma’s injectable facility at Gujarat

01 Sep 2022 Evaluate

United States Food and Drug Administration (USFDA) has concluded inspection at Alembic Pharmaceuticals’ Injectable Facility (F-3) located at Karkhadi, Gujarat. USFDA has conducted inspection from August 18, 2022 to August 30, 2022 and issued Form 483 with 2 observations. None of the observations are related to data integrity and management believes that they are addressable. The company is preparing the response to the observations, which will be submitted to the USFDA within stipulated period. The company is committed to maintain the highest quality standards and compliance at all times.

Alembic Pharmaceuticals, a vertically integrated research and development pharmaceutical company, has been at the forefront of Healthcare since 1907.

Alembic Pharma Share Price

785.40 8.05 (1.04%)
08-May-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1847.30
Dr. Reddys Lab 1293.25
Cipla 1347.70
Zydus Lifesciences 938.90
Lupin 2377.90
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×